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Abstract
Purpose We investigated the effect of glutamine (Gln) and an
elemental diet (ED) on chemotherapy-induced oral mucositis
in esophageal cancer patients.
Methods Thirty patients were randomized to the control
group (no treatment: n = 10), Gln group (oral intake of
8910 mg Gln/day: n = 10), or Gln plus ED group (total oral
intake of 8862 mg Gln/day, including the Gln in ED: n = 10).
Oral administration of Gln and ED began 1 week before che-
motherapy and continued during treatment. Oral mucositis
was evaluated during 2 cycles of chemotherapy using Com-
mon Terminology Criteria for Adverse Events v3.0.
Results The incidence of grade ≥2 oral mucositis was 60 % in
the control group, 70 % in the Gln group, and 10 % in the Gln
plus ED group. Gln plus ED showed a significant preventive
effect on the development and severity of oral mucositis. By
multivariate analysis, Gln plus ED and cancer stage were in-
dependent factors affecting chemotherapy-induced oral muco-
sitis. The percentage of change in body weight and diamine
oxidase activity from before chemotherapy was higher in the
Gln plus ED group than in the control group.
Conclusions Oral administration of Gln plus ED may prevent
chemotherapy-induced oral mucositis in esophageal cancer
patients.
Keywords Esophageal cancer . Chemotherapy .Mucositis .
Glutamine . Elemental diet
Introduction
Although morbidity and mortality rates after surgical treat-
ment for advanced esophageal cancer have decreased, the 5-
year survival rate after curative surgery is still only 20–36 %
[1]. In patients with operable esophageal cancer, there is evi-
dence supporting the use of preoperative chemotherapy or
preoperative chemoradiation [2–4]. Patients with unresectable
or inoperable esophageal disease have also been treated with
various chemotherapy strategies [5]. Chemotherapy can sig-
nificantly improve the clinical outcomes of cancer patients,
but it can also result in serious adverse effects [6]. In esopha-
geal cancer, treatment with 5-fluorouracil (5-FU)/cisplatin
plus docetaxel (DCF) is reported to be associated with in-
creased response rates but also with an increased incidence
of toxicities, the most common of which are hematological
and gastrointestinal (GI) [7, 8]. Triplet regimen had high re-
sponse rate and also was associated with higher rates of grade
of stomatitis [9]. GI toxicities caused by chemotherapy can
negatively affect patients’ nutritional status by decreasing
food intake and can result in a delay or discontinuation of
chemotherapy [10], thereby negatively affecting tumor re-
sponse to treatment; in addition, GI toxicities could lead to a
delay in elective surgery and increase the risk of operative
complications. Oral mucositis, one of the most common GI
toxicities, results in increased pain, difficulty in swallowing,
nutritional compromise, and an increased risk of infection.
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Nishimura et al. [11] reported that the incidence of oral mu-
cositis (Common Terminology Criteria for Adverse Events
[CTCAE] [12] grade ≥1) was the highest during chemothera-
py for breast cancer (76.5 %), followed by chemotherapy for
head and neck cancer (67.7 %), colorectal cancer (63 %),
esophageal cancer (57.8 %), and malignant lymphoma
(42.9 %). Several reports indicated that the glutamine (Gln)
decreased only the subjective symptoms of stomatitis [13–15].
Even if there was objective effect, a large amount of Gln was
administered [16, 17]. It was difficult to formulate a large
amount of Gln in the practical treatment. Recently, efficacy
of elemental diet (including Gln) for chemotherapy-induced
oral mucositis in esophageal cancer (grade 1 stomatitis) and
colorectal cancer (grade 1–3 stomatitis) patients was reported,
and their concept of treatment were after experience of stoma-
titis [18, 19]. In our pilot study, oral Gln and elemental diet
(ED) which was administered from before starting of chemo-
therapy was found to help maintain patients’ nutritional status
and to reduce the incidence of oral mucositis in esophageal
cancer (unpublished data).
We therefore conducted a randomized phase II study for
investigation of efficacy and safety at Gln plus ED or Gln
alone compared to no treatment on oral mucositis in patients
with esophageal cancer undergoing chemotherapy.
In addition, because oral mucositis is reported to be caused
by chemotherapy-induced mucosal damage or infection and
inflammation by indigenous oral bacteria [20], we also mea-
sured and compared the mucosal integrity and degree of in-
flammation between the treatment groups.
Methods
Ethical considerations
This trial was conducted in accordance with the World Med-
ical Association Declaration of Helsinki and registered with
the University Hospital Medical Information Network Clini-
cal Trials Registry (UMIN000008338). The study protocol
was approved by the Ethics Committee of Gifu University
Hospital, and written informed consent was obtained from
all patients.
Eligibility criteria
To be eligible for the study, patients had to be at least 18 years
of age at the time of registration and have histologically or
cytologically confirmed esophageal squamous cell carcinoma
or adenocarcinoma.
Disease staging was defined according to the Japanese So-
ciety for Esophageal Disease guidelines (10th edition) [21].
Patients also had to have an Eastern Cooperative Oncology
Group performance status of 0–1 [22], a life expectancy of
>12 weeks, and adequate liver, bone marrow, renal, and car-
diovascular function (serum bilirubin ≤1.5 mg/dL, neutrophil
count ≥1500/mm3, serum aspartate aminotransferase and ala-
nine aminotransferase levels ≤ twice the upper limit of normal
range, platelet count ≥10 × 104/mm3, hemoglobin ≥8.0 g/dL,
and creatinine ≤1.2 mg/dL [or creatinine clearance >60 mL/
min]).
Patients previously treated with chemotherapy for malig-
nant disease or irradiation to major bone areas were excluded
from the study. The major exclusion criteria included serious
concomitant illness, symptomatic infectious disease, severe
drug allergy, symptomatic peripheral neuropathy, or uncon-
trolled diabetes mellitus.
Study drug
In the Gln group, patients received 8910 mg of Gln daily. In
the Gln plus ED group, patients received 6930 mg of Gln and
one pack of Elental® (300 mL/day [300 kcal/day]; Supple-
mentary Table S1) daily, based on a previous study [1]. In
the Gln plus ED group, the amount of total Gln taken daily
was equal to that in the Gln group. In all patients, calorie
intake was restricted to 30 kcal kg−1 day−1.
Patients received either DCF or docetaxel/nedaplatin/S-1
(DGS) [7, 23] chemotherapy regimens.
Patients undergoing DCF chemotherapywere administered
35 mg/m2 of docetaxel and 40 mg/m2 of cisplatin on days 1
and 15 and 400 mg/m2 of 5-FU on days 1–5 and 15–19 of
every 28-day cycle. Patients undergoing DGS chemotherapy
were administered 35 mg/m2 of docetaxel and 40 mg/m2 of
nedaplatin on day 7 and 80 mg/m2 of S-1 on days 1–14 of
every 28-day cycle. Except for patients with stage IVb dis-
ease, all patients underwent surgery.
Study design
This study is a randomized phase II study for investigation of
efficacy and safety at Gln + ED treatment. We could estimate
the effect size for each arm. We will plan a multicenter ran-
domized phase III study using these estimated effect sizes for
calculation of sample size. The primary objective of this study
was to determine the effect of Gln and Gln plus ED on the
incidence grade of oral mucositis [9] during 2 cycles of che-
motherapy. After confirmation of eligibility, patients were ran-
domized to the chemotherapy-only group (control), Gln group
(Gln) (marzulene-S®; Ajinomoto Pharmaceuticals Co., Ltd.),
or Gln plus ED (Elental®; Ajinomoto Pharmaceuticals Co.,
Ltd) group (Gln plus ED). In the Gln and Gln plus ED groups,
each drug was administered orally beginning 1 week before
chemotherapy and was continued between rounds of chemo-
therapy. Patients were assigned in a 1:1:1 ratio to receive Gln,
Gln plus ED, or no additional treatment (control). During the
chemotherapy cycles, patients continued to receive Gln or Gln
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plus ED every day. Total daily calories consumed were re-
stricted to 30 kcal/body weight in all patients, and the amount
of food intake was directly reported by patients. In cases
where food consumption was 70 % or less of the defined
amount for 3 days, the patient was withdrawn from the study
because of the significant difference in calorie intake. Oral
mucositis was assessed by two trained physicians who were
blinded whether administered or not. The severity grade was
assessed before chemotherapy, after the first cycle of chemo-
therapy, and after the second cycle of chemotherapy. Before
chemotherapy, a dentist has performed oral care for dental
caries and periodontal disease to all the patients. Patient edu-
cation in oral selfcare was performed by nurses, too. We also
measured weight; plasma diamine oxidase (DAO) activity,
which is a reliable indicator of intestinal mucosal integrity
[24]; C-reactive protein (CRP) level, which was used as an
inflammatory indicator; turnover rate of plasma proteins
(prealbumin, transferrin, and retinol binding protein [RBP]),
as indicators of nutritional status; and plasma concentration of
various amino acids such as Gln and histidine. We assessed
tumor response according to the Response Evaluation Criteria
in Solid Tumors guidelines [25] after 2 cycles of chemother-
apy. A barium meal study, endoscopy, ultrasonography, and
computed tomography or magnetic resonance imaging were
used to evaluate the response status of measurable lesions. We
defined complete response as complete disappearance of all
clinically detectable malignant disease and partial response as
a >30 % decrease in the sum of the perpendicular diameters of
all measurable lesions present for at least 4 weeks. We defined
progressive disease as either a >20 % increase in the sum of
the products of measurable lesions over the smallest sum ob-
served or the appearance of new lesions. Stable disease did not
qualify as complete response, partial response, or progressive
disease.We investigated the incidence of any complications at
the time of operation.
Other adverse events
Side effect was assessed using the National Cancer Institute
CTCAE version 3.0 [12].
Statistical analysis
The primary endpoint was the pairwise comparison of inci-
dence grade of mucositis between each of the two experimen-
tal arms (Gln group and Gln plus ED group) and the control
arm. Secondary endpoints included a comparison of patient
demographics and confirmation of laboratory changes. For the
primary endpoint, the Mann-Whitney U test with Bonferroni
correction was used to assess the reduction of mucositis inci-
dence. A proportional odds model was used to the evaluation
of treatment effect (Gln and Gln + ED) and adjusted effect of
five covariates (age, sex, cancer stage, treatment, and bodymass
index). The estimated model may have multicollinearity, so we
applied backward stepwise method using Akaike’s information
criteria as variable selection measure. Secondary endpoints
were assessed using Dunnett’s multiple comparison method.
Statistical analyses were performed using R version 3.1.1. A P
value <0.05 was considered to be statistically significant.
Results
Patients
From June 2010 toMarch 2013, 30 patients were enrolled and
randomized to either the Gln plus ED group (n = 10), Gln
group (n = 10), or control group (n = 10). The baseline char-
acteristics of the patients are shown in Table 1. All included
patients consumed more than 70 % of the established calorie
requirements. With respect to the amount of anti-cancer drugs
that was actually administered, all 30 patients received full
doses in the first cycle; in the second cycle, 2 patients in the
control group, 1 patient in the Gln group, and 2 patients in the




During this study, oral mucositis of grade ≥2 developed in
approximately 60 % of patients in the control group, and the
incidence of oral mucositis was significantly lower in the Gln
plus ED group (10 %) than in the control group (Fig. 1a). In
addition, during the first cycle of chemotherapy, the incidence
of oral mucositis was significantly lower in the Gln plus ED
group than in the control group (P = 0.040) (Fig. 1b). How-
ever, no significant difference between the control and Gln
plus ED groups was observed during the second cycle of
chemotherapy (Fig. 1c). On the other hand, no significant
difference between the control and Gln groups was observed
during this study (Fig. 1a, b, c). The results of the multivariate
analysis demonstrated that in addition to Gln plus ED (odds
ratio = 0.1, P = 0.02), cancer stage (odds ratio = 13.3,
P = 0.01) was an independent factor affecting mucositis grade
during chemotherapy (Table 2).
Laboratory tests
No significant differences in the absolute values of laboratory
tests before chemotherapy, except for plasma DAO (5.81 in
the control group, 6.63 in the Gln group, and 3.43 in the Gln
plus ED group, respectively), were observed among the
groups. The Gln plus ED group showed a significant increase
in DAO activity during chemotherapy (approximately 1.3
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times the DAO activity measured before chemotherapy)
(Table 3). In the control group, there was significant weight
loss during chemotherapy (Δmean = −5.4 %, P = 0.01). On
the other hand, body weight was maintained in the Gln plus
ED group, and changes in body weight were significantly
different between the Gln plus ED and control groups (1.70
vs. −5.40 %, respectively; P = 0.01) (Table 3). T helper 1 cells
and immunoglobulin A levels were significantly reduced dur-
ing chemotherapy (−27.63 and −25.90 %, respectively). How-
ever, there was no significant difference in the rate of change
of these values observed among the groups (Table 3).
During chemotherapy, there were no significant differences
in other parameters, such as CRP and rapid turnover proteins
(prealbumin, transferrin, RBP), which are known to reflect
systemic inflammatory status and nutritional index. After re-
ceiving chemotherapy, the plasma concentrations of various
amino acids were measured, and the plasma concentrations of
some amino acids tended to be lower in the control group than
in the other groups. For example, plasma Gln tended to be
higher in the Gln and Gln plus ED groups than in the control
group (−3.64, 9.91, and 9.59 %, respectively; Table 3).
Response rate
The treatment did not negatively affect patients’ response rates
to chemotherapy (Table 4). In the Gln plus ED group, the
response rate was 90 % (complete response, 10 %; partial
response, 80 %; stable disease, 10 %). In the control and Gln
groups, the response rates were 70 and 80 %, respectively
(control group: complete response 10 %, partial response
60 %, stable disease 20 %, progressive disease 10 %; Gln
group: complete response 30 %, partial response 50 %, stable
disease 20 %).
Adverse events and operative complications
Detailed information on the adverse events reported in the
control, Gln, and Gln plus ED groups is presented in Table 5.
In all groups, the most common grade 3/4 hematological tox-
icity was neutropenia.
Non-hematological toxicities other than oral mucositis
were mild in all groups (including grade 2 diarrhea, anorexia,
and alopecia). In one case in the Gln group and two cases in
the control group, the second cycle of chemotherapy was de-
layed for 3–4 days because of grade 3 mucositis. Surgical
resection was performed in seven cases in the Gln plus ED
group, in eight cases in the Gln group, and in nine cases in the
control group. Postoperative complications were not observed
in any group, and administration of ED did not interfere with
any planned radical surgeries.
Discussion
This is the first study to show that Gln plus ED can prevent
oral mucositis in patients receiving chemotherapy. Moreover,
the results of the multivariate analysis demonstrated that Gln
plus ED and cancer stage were independent factors affecting
Table 1 Characteristics of patients
Group Control (n = 10) Gln (n = 10) Gln plus ED (n = 10)
Regimen DCF 4 4 5
DGS 6 6 5
Daily calorie intake including ED (kcal) 2100 2100 2100
(1800–2100) (1600–2100) (2100–2100)
Age (years) 68 73.5 75
49–82 68–78 58–83
Sex Female 1 3 0
Male 9 7 10
Cancer site Ce 1, Lt 3, Mt 6 Ae 1, Lt 2, Mt 4, Mt-Ut 2, Ut 1 Lt 2, Mt 8
Radiation Yes 0 0 0
No 10 10 10
Stage II 2 4 1
III 4 1 5
IVa 3 3 0
IVb 1 2 4
BMI 21.75 (18.37–25.59) 22.42 (16.60–25.20) 21.08 (14.60–24.20)
Ae abdominal esophageal site, BMI body mass index, Ce cervical esophageal site, DCF docetaxel + cisplatin + 5-fluorouracil, DGS docetaxel +
nedaplatin + S-1, ED elemental diet,Gln glutamine, Lt lower thoracic esophageal site,Mtmiddle thoracic esophageal site,Ut upper thoracic esophageal
site
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mucositis grade during chemotherapy. Additionally, in our
study, Gln plus ED had beneficial effects on the integrity of
the intestinal mucosa, as indicated byDAOmeasurements and
body weight. In the Gln plus ED group, there was a significant
difference during chemotherapy in the inhibitory effect
against stomatitis. But in cycle 2, there was no significance
of prevention. Probably because of the dose reduction in five
cases in cycle 2 and also small sample size, significant differ-
ence was not seen in cycle 2. When enteral nutrients are ad-
ministered, poor compliance becomes a serious problem.
However, in this study, all patients completed the scheduled
treatment with ED, which suggested good patient compliance.
One of the reasons why the high intake ratio was maintained
may be the choices offered to patients on how to take ED, such
as adding flavoring agents or a jelly mix. Previous reports
indicated that the Gln decreased the subjective symptoms of
stomatitis in chemotherapy, radiotherapy, and hematopoietic
stem cell transplantation [13–15]. Our study showed that Gln
alone did not have a preventive effect against oral mucositis,
in spite of the same Gln content as Gln plus ED. This was in
contrast to previous studies that reported that oral Gln reduced
the incidence and severity of mucositis [13–17]. In our trial,
marzulene® (which is largely composed of Gln) was admin-
istered at a dose of 8910 mg/day as an oral Gln formulation.
Previous reports administered Gln doses of 30 and 24 g/day
[16, 17], respectively; thus, the dose used in this study may be
inadequate to prevent oral mucositis. Saforis™ (Eisai Co.,
Ltd.), which is composed of Gln in a novel, proprietary, drug
delivery system, is used for preventing oral mucositis. Peter-
son et al. [26] reported that Saforis™ significantly prevented
oral mucositis in cancer patients receiving chemotherapy
when administered at a dose of 2.5 g, three times a day, for
14 days. Comparing the local concentration of marzulene®
with that of Saforis™ is difficult, but Saforis™ might have a
higher concentration than marzulene® in epithelial oral muco-
sal cells because of its ability to facilitate the uptake of Gln by
more than 100-fold. May et al. suggested that the mixture of
hydroxyl-methylbutyrate, arginine, and Gln (HMB/Arg/Gln
16 g) was effective against cancer cachexia [27]. Additionally,
this paper suggested that one of the mechanisms of this effect
was that Gln is a substrate for enterocytes and lymphocytes,
acting to improve nitrogen retention, lower the incidence of
infections, and decrease tumor growth and chemotherapy tox-
icity. However, this mixture has a higher Gln content than the
dose used in this study. Therefore, the Gln dose in this study
might be inadequate to prevent oral mucositis. Gln plus ED
prevented oral mucositis in patients receiving chemotherapy,
despite the fact that this regimen included the same amount of
Gln as marzulene® alone. It cannot be ruled out that absorp-
tive kinetics may be different between marzulene® and
marzulene® plus ED, but various amino acids, including
Gln, in ED might have resulted in the prevention of oral mu-
cositis. Supportively, efficacy of ED for chemotherapy-
induced oral mucositis in esophageal cancer and colorectal
cancer patients was recently reported, but their concept of
treatment was after experience of stomatitis [18, 19].
Although the pathogenesis of mucositis remains to be
completely elucidated, it has been reported that chemotherapy
damages DNA through production of reactive oxygen species,
induces apoptosis by upregulating the expression of intracel-
lular molecules such as NF-kB, and produces several cyto-
kines such as interleukin-1 beta, interleukin-6 (IL-6), and tu-
mor necrosis factor-alpha (TNF-alpha) (direct mechanism)
[20]. The protective effect of ED on mucosal tissue in Crohn’s
disease has been widely reported [28, 29]. In clinical practice,
ED has a clear suppressive effect on clinical and endoscopic
Fig. 1 Incidence of oral mucositis during chemotherapy (%). a During
2 cycles of chemotherapy. b During the first cycle of chemotherapy. c
During the second cycle of chemotherapy. ED elemental diet,G grade, ns
not significant
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disease activities and the levels of mucosal inflammatory cy-
tokines, such as interleukin-1 beta, IL-6, and TNF-alpha [28].
Moreover, histidine, one of the constituent amino acids of ED,
inhibited lipopolysaccharide-induced TNF-alpha and IL-6
production by mouse macrophages in a concentration-
dependent manner [29]. Therefore, in chemotherapy-induced
Table 2 Multivariate analysis for independent factors affecting increased mucositis grade during chemotherapy
Factor Number of patients Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
Gln With 20 4.1 (0.6–33.7) 0.17 4.0 (0.7–29.6) 0.15
Without 10
Gln plus ED With 20 0.1 (0.0–0.7) 0.03* 0.1 (0.0–0.6) 0.02*
Without 10
Age, years <70 16 3.1 (0.7–16.5) 0.16 3.1 (0.7–16.1) 0.15
≥70 14
Sex Male 26 0.9 (0.1–7.7) 0.95 – –
Female 4
Cancer stage IVa,b 13 14.6 (1.9–150.0) 0.01* 13.3 (1.9 –123.2) 0.01*
II–III 17
Treatment First line 7 0.2 (0.0–2.1) 0.19 0.2 (0.0–1.6) 0.13
NAC 23
BMI <21 13 1.9 (0.4–9.6) 0.44 – –
≥21 17
BMI body mass index, ED elemental diet, Gln glutamine, NAC neoadjuvant chemotherapy
*p<0.05
Table 3 Percentage changes in laboratory test results after the first and second cycles of chemotherapy compared to pre-chemotherapy
Post first cycle Post second cycle
Δmean (%) P value Δmean (%) P value
Control Gln Gln plus ED Gln Gln plus ED Control Gln Gln plus ED Gln Gln plus ED
Weight −3.54 −2.9 −0.38 0.89 0.11 −5.40 −3.9 1.70 0.73 0.01*
Prealbumin 20.59 2.61 8.79 0.59 0.79 16.74 7.89 21.34 0.82 0.95
RBP 33.54 32.61 19.75 1.00 0.91 32.47 27.66 26.25 0.96 0.94
Transferrin −6.39 −18.35 −6.44 0.34 1.00 −8.48 −15.94 −2.38 0.67 0.76
Ferritin 102.93 186.13 183.79 0.41 0.43 283.18 246.26 383.87 0.98 0.85
Lymphocyte counts −22.41 −27.82 −23.99 0.91 0.99 −14.37 −21.94 4.59 0.83 0.34
DAO −6.81 −25.26 33.7 0.46 0.04* −10.13 −27.17 26.68 0.56 0.10
HLA-DR −4.35 −11.52 −11.04 0.72 0.75 −1.61 −2.84 −4.04 0.99 0.97
Th1 −20.79 −20.52 −17.06 1.00 0.86 −27.63 −26.08 −26.69 0.96 0.98
Th2 39.95 −7.18 −18.26 0.45 0.31 15.64 −3.97 −37.48 0.74 0.15
Th1/Th2 −2.51 1.9 30.14 0.98 0.38 −5.72 10.94 58.06 0.90 0.25
CD4 61.66 22.77 28.1 0.20 0.29 52.35 26.57 −0.05 0.46 0.07
CD8 −19.94 −14.38 −15.5 0.84 0.90 −15.35 −14.18 −2.77 0.99 0.28
CD4/CD8 ratio 139.99 103.77 62.91 0.87 0.54 96.77 97.47 8.99 1.00 0.37
CRP 328.85 1508.77 268.03 0.17 0.99 842.93 1592.76 68.73 0.55 0.53
Albumin −2.73 −10.17 −8.27 0.19 0.37 −4.21 −12.14 −4.24 0.16 1.00
IgA −22.42 −16.09 −22.73 0.51 1.00 −25.90 −23.75 −24.1 0.960 0.97
Glutamine −13.64 2.9 0.87 0.23 0.31 −3.64 9.91 9.59 0.20 0.21
Histidine −14.98 −4.50 −0.29 0.59 0.37 −13.67 2.22 0.03 0.16 0.25
CRP C-reactive protein,DAO diamine oxidase, ED elemental diet,Gln glutamine, IgA immunoglobulin A, RBP retinol binding protein, Th T helper cell
*p<0.05
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mucositis, it has been hypothesized that ED might also have a
mucosal protective effect and prevent oral mucositis. In fact,
our trial showed significantly higher levels of DAO activity,
an indicator of intestinal mucosal integrity, in the Gln plus ED
group than in the control group. DAO activity was previously
reported to be an index of intestinal mucosal integrity. In
humans and rodents, DAO is detected in various tissues, in-
cluding the small intestine and kidney, but may also be found
in the plasma [30]. Plasma DAO activity correlated with DAO
activity in the villi of small intestinal mucosa in rats [30] and
also correlated with the severity of small intestinal mucosal
lesions induced by anti-cancer drugs [31, 32]. Recently, mea-
suring DAO activity in gastric cancer patients was reported to
be useful not only as an indicator of mucosal injury but also
for the evaluation of coinciding GI tract toxicities induced by
anti-cancer drugs, such as 5-FU [31].
Therefore, the effect of ED on mucositis might result from
maintaining mucosal integrity, indicated by higher DAO ac-
tivity. In this study, from the results of the multivariate analy-
sis, cancer stage IV was an independent influential factor
affecting increased mucositis grade during chemotherapy. Ac-
cordingly, previous reports have demonstrated increased
levels of plasma cytokines, such as interleukin-1 beta, IL-6,
and TNF-alpha in patients with advanced cancer stages. Al-
though daily calorie intake was restricted to the same amount
among the three groups in our trial, body weight was signifi-
cantly decreased in the control group, and body weight in the
Gln plus ED group was maintained after chemotherapy. The
maintenance of body weight in the Gln plus ED group may be
explained by two possible mechanisms. First, ED and Gln
may have maintained mucosal integrity not only in the oral
cavity but also in the GI tract, thereby resulting in maintained
nutrient absorption. Second, ED included an amino acid for-
mulation and not protein. Patients may be unable to digest
food because of chemotherapy-induced GI toxicities. In this
situation, amino acids may be more suitable than proteins to
provide nutrients, as proteins require digestion. Levels of rap-
id turnover proteins, known to reflect nutritional index, were
not dependent on body weight loss in the control group. Pre-
viously, Georgiannos et al. suggested that patients who lost
weight (>7.5 %) had higher plasma CRP levels and lower
prealbumin levels (P < 0.05) compared to both weight-stable
cancer patients and controls [33]. In our trial, mean body
weight loss was 5.4 % in the control group, and lower than
7.5 %. Moreover, no significant increase in CRP levels during
chemotherapy was observed in the control group. Therefore,
rapid turnover proteins such as prealbumin were not signifi-
cantly decreased in the control group in our study.
It was recently reported that enteral administration of ami-
no acid mixtures enabled normal amino acid absorption in
patients with mucositis [34]. On the other hand, it was also
reported that absorption of long-chain fatty acids might have
been reduced in patients with GI mucositis [35]. This also
suggested that ED, which is composed of amino acids (not
Table 4 Chemotherapy
response rates in each
group
CR PR SD PD
Control 1 6 2 1
(10) (60) (20) (10)
Gln 3 5 2 0
(30) (50) (20) (0)
Gln + ED 1 8 1 0
(10) (80) (10) (0)
Data are presented as the number of pa-
tients. Percentage are noted in parentheses
CR complete response, PR partial re-
sponse, SD stable disease, PD progressive
disease, Gln glutamine, ED elemental diet
Table 5 Adverse events according to treatment group

























Hematological adverse events Leukopenia 1 2 1




Diarrhea 4 4 1 4
Anorexia 4 2 2 3
Dysgeusia 1 2 1




ED elemental diet, Gln glutamine
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including protein) and a small quantity of fatty acids, might be
the best source of enteral nutrients during cancer chemother-
apy. In our trial, we measured plasma concentrations of vari-
ous amino acids. However, no significant differences in the
concentrations of plasma Gln or other amino acids were ob-
served either before, between, or after the administration of
ED and/or Gln in any groups. This may be due to the fact that
Gln and other amino acids are almost locally consumed as a
source of energy or anti-inflammatory effects in the gastroin-
testinal tract.
The above mechanisms of action of Gln plus ED on oral
mucositis are completely speculative. Therefore, further ex-
perimental studies are needed to confirm the mechanism of
the action of ED and/or Gln on mucositis. Moreover, one of
the limitations of our study was the small sample size studied
at a single site. Hence, we are currently conducting a large,
multicenter study to confirm the beneficial effects of ED on
chemotherapy-induced oral mucositis in esophageal cancer
patients.
In conclusion, Gln plus ED may prevent chemotherapy-
induced oral mucositis in esophageal cancer patients, and this
effect may contribute to the maintenance of intestinal mucosal
integrity and body weight during chemotherapy. These results
would suggest that this will be tempered with recommenda-
tion for a multicenter RCT.
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